{"cluster": 36, "subcluster": 53, "abstract_summ": "(11,12) Until this point, no single agent has shown a survival benefit against SARS-CoV-2 and it is possible that monotherapy may not suppress inflammation enough to overcome the COVID-19 related cytokine storm and hyper-inflammation.The severity and mortality of the disease is associated with a high level of release of cytokine in the patients which is known as CRS (cytokine release syndrome) or cytokine storm syndrome.Approximately 15% of patients with coronavirus disease 2019 (COVID-19) experience severe disease, and 5% progress to critical stage that can result in rapid death.As interleukin-6 (IL-6) acts as a key driver of the inflammation associated with coronavirus disease 2019 (COVID-19), IL-6 and IL-6 receptor (IL-6R) inhibition appear to be promising targets for the treatment of COVID-19 patients.Furthermore, considering the common role of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway in AT1-R expressed on peripheral tissues and cytokine receptors on the surface of immune cells, potential targeting of this pathway using JAK inhibitors (JAKinibs) is suggested as a promising approach in patients with COVID-19 who are admitted to hospitals.", "title_summ": "BTK inhibitors in cancer patients with COVID19: \"The winner will be the one who controls that chaos\" (Napoleon Bonaparte).BTK/ITK dual inhibitors: Modulating immunopathology and lymphopenia for COVID-19 therapy.[Inhibitors of RAS Might Be a Good Choice for the Therapy of COVID-19 Pneumonia].Involvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic option against COVID-19.Incretin-Based Therapies Role in COVID-19 Era: Evolving Insights.SGP130FcInhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatmentIL-6 Inhibitors in the Treatment of Serious COVID-19: A Promising Therapy?JAK Inhibition as a New Treatment Strategy for Patients with COVID-19Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19Potential Role of Anti-interleukin (IL)-6 Drugs in the Treatment of COVID-19: Rationale, Clinical Evidence and RisksA potential role for Galectin-3 inhibitors in the treatment of COVID-19Combined IL-6 and JAK-STAT inhibition therapy in COVID-19 related sHLH, potential game changer.Baricitinib restrains the immune dysregulation in COVID-19 patientsSARS-CoV-2 and COVID-19: is interleukin-6 (IL-6) the 'culprit lesion' of ARDS onset?What is there besides Tocilizumab?", "title_abstract_phrases": "The urgent need for treatments for patients with severe disease support expedited investigation of ruxolitinib for patients with COVID-19.IL-6 Inhibitors in the Treatment of Serious COVID-19: A Promising Therapy?At present, there are no proven agents for treatment of coronavirus disease (COVID-19).Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatmentApproximately 15% of patients with coronavirus disease 2019 (COVID-19) experience severe disease, and 5% progress to critical stage that can result in rapid death.Furthermore, considering the common role of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway in AT1-R expressed on peripheral tissues and cytokine receptors on the surface of immune cells, potential targeting of this pathway using JAK inhibitors (JAKinibs) is suggested as a promising approach in patients with COVID-19 who are admitted to hospitals.Considering the proven role of cytokine dysregulation in causing this hyperinflammation in the lungs with IL-6 being a key driver, particularly in seriously ill COVID-19 patients, it is crucial to further explore selective cytokine blockade with drugs like the IL-6 inhibitors tocilizumab, sarilumab, and siltuximab.As interleukin-6 (IL-6) acts as a key driver of the inflammation associated with coronavirus disease 2019 (COVID-19), IL-6 and IL-6 receptor (IL-6R) inhibition appear to be promising targets for the treatment of COVID-19 patients."}